348 related articles for article (PubMed ID: 8315430)
1. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy.
Weaver CH; Appelbaum FR; Petersen FB; Clift R; Singer J; Press O; Bensinger W; Bianco J; Martin P; Anasetti C
J Clin Oncol; 1993 Jul; 11(7):1329-35. PubMed ID: 8315430
[TBL] [Abstract][Full Text] [Related]
2. High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy.
Demirer T; Weaver CH; Buckner CD; Petersen FB; Bensinger WI; Sanders J; Clift RA; Lilleby K; Anasetti C; Martin P
J Clin Oncol; 1995 Mar; 13(3):596-602. PubMed ID: 7884421
[TBL] [Abstract][Full Text] [Related]
3. Carmustine, Ara C, cyclophosphamide and etoposide with autologous bone marrow transplantation in relapsed or refractory lymphoma: a dose-finding study.
Snyder MJ; Johnson DB; Daly MB; Giguere JK; Harman GH; Harden EA; Johnson RA; Leff RS; Mercier RJ; Messerschmidt GL
Bone Marrow Transplant; 1994 Oct; 14(4):595-600. PubMed ID: 7858534
[TBL] [Abstract][Full Text] [Related]
4. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.
Wheeler C; Antin JH; Churchill WH; Come SE; Smith BR; Bubley GJ; Rosenthal DS; Rappaport JM; Ault KA; Schnipper LE
J Clin Oncol; 1990 Apr; 8(4):648-56. PubMed ID: 2313334
[TBL] [Abstract][Full Text] [Related]
5. High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma.
Lazarus HM; Crilley P; Ciobanu N; Creger RJ; Fox RM; Shina DC; Bulova SI; Gucalp R; Cooper BW; Topolsky D
J Clin Oncol; 1992 Nov; 10(11):1682-9. PubMed ID: 1403051
[TBL] [Abstract][Full Text] [Related]
6. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease.
Reece DE; Barnett MJ; Connors JM; Fairey RN; Fay JW; Greer JP; Herzig GP; Herzig RH; Klingemann HG; LeMaistre CF
J Clin Oncol; 1991 Oct; 9(10):1871-9. PubMed ID: 1919637
[TBL] [Abstract][Full Text] [Related]
7. Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies.
Stahel RA; Jost LM; Cerny T; Pichert G; Honegger H; Tobler A; Jacky E; Fey M; Platzer E
J Clin Oncol; 1994 Sep; 12(9):1931-8. PubMed ID: 7521907
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease.
Jagannath S; Armitage JO; Dicke KA; Tucker SL; Velasquez WS; Smith K; Vaughan WP; Kessinger A; Horwitz LJ; Hagemeister FB
J Clin Oncol; 1989 Feb; 7(2):179-85. PubMed ID: 2644397
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma.
Adkins DR; Salzman D; Boldt D; Kuhn J; Irvin R; Roodman GD; Lyons R; Smith L; Freytes CO; LeMaistre CF
J Clin Oncol; 1994 Sep; 12(9):1890-901. PubMed ID: 7916039
[TBL] [Abstract][Full Text] [Related]
10. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
Wheeler C; Khurshid A; Ibrahim J; Elias A; Mauch P; Ault K; Antin J
Leuk Lymphoma; 2001 Feb; 40(5-6):499-509. PubMed ID: 11426523
[TBL] [Abstract][Full Text] [Related]
11. Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt's lymphomas in adult patients.
Jost LM; Jacky E; Dommann-Scherrer C; Honegger HP; Maurer R; Sauter C; Stahel RA
Ann Oncol; 1995 May; 6(5):445-51. PubMed ID: 7545428
[TBL] [Abstract][Full Text] [Related]
12. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease.
Vose JM; Sharp G; Chan WC; Nichols C; Loh K; Inwards D; Rifkin R; Bierman PJ; Lynch JC; Weisenburger DD; Kessinger A; Armitage JO
J Clin Oncol; 2002 May; 20(9):2344-52. PubMed ID: 11981006
[TBL] [Abstract][Full Text] [Related]
13. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.
van Besien K; Tabocoff J; Rodriguez M; Andersson B; Mehra R; Przepiorka D; Dimopoulos M; Giralt S; Suki S; Khouri I
Bone Marrow Transplant; 1995 Apr; 15(4):549-55. PubMed ID: 7655380
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide.
Wheeler C; Strawderman M; Ayash L; Churchill WH; Bierer BE; Elias A; Gilliland DG; Antman K; Guinan EC; Eder JP
J Clin Oncol; 1993 Jun; 11(6):1085-91. PubMed ID: 8099120
[TBL] [Abstract][Full Text] [Related]
15. Comparison of preparative transplantation regimens using carmustine/etoposide/cisplatin or busulfan/etoposide/cyclophosphamide in lymphoid malignancies.
Crilley P; Lazarus H; Topolsky D; Ciobanu N; Creger RJ; Fox RM; Bulova SI; Shina DC; Gucalp R; Cooper BW
Semin Oncol; 1993 Aug; 20(4 Suppl 4):50-4; quiz 55. PubMed ID: 8342076
[TBL] [Abstract][Full Text] [Related]
16. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
Law LY; Horning SJ; Wong RM; Johnston LJ; Laport GG; Lowsky R; Shizuru JA; Blume KG; Negrin RS; Stockerl-Goldstein KE
Biol Blood Marrow Transplant; 2006 Jul; 12(7):703-11. PubMed ID: 16785059
[TBL] [Abstract][Full Text] [Related]
17. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study.
Martelli M; Vignetti M; Zinzani PL; Gherlinzoni F; Meloni G; Fiacchini M; De Sanctis V; Papa G; Martelli MF; Calabresi F; Tura S; Mandelli F
J Clin Oncol; 1996 Feb; 14(2):534-42. PubMed ID: 8636768
[TBL] [Abstract][Full Text] [Related]
18. [High dose chemoradiotherapy and autologous bone marrow transplantation (ABMT) as a first line therapy to treat advanced adult high-grade malignant T-cell non-Hodgkin's lymphoma--a pilot clinical study].
Wu GQ
Zhonghua Zhong Liu Za Zhi; 1993 Jan; 15(1):47-51. PubMed ID: 7687533
[TBL] [Abstract][Full Text] [Related]
19. Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation.
Attal M; Canal P; Schlaifer D; Chatelut E; Dezeuze A; Huguet F; Payen C; Pris J; Laurent G
J Clin Oncol; 1994 Jan; 12(1):141-8. PubMed ID: 8270970
[TBL] [Abstract][Full Text] [Related]
20. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.
Mills W; Chopra R; McMillan A; Pearce R; Linch DC; Goldstone AH
J Clin Oncol; 1995 Mar; 13(3):588-95. PubMed ID: 7884420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
